July 2019

Board of Directors

Guido Guidi and Robert Karsunky have been elected to Cellestia’s Board of Directors. Guido Guidi is the new Chairman of the Board.

June 2019

9th International Conference – NOTCH Targeting in Cancer

Meet our CSO Rajwinder Lehal and attend the following sessions, at Grecian Park Hotel, Konnos Bay, Cyprus (June 26–28, 2019).

On 28th June, he will be chairing the Notch Therapeutics workshop together with Lucio Miele. He will also be giving a talk in Session 7 (Novel Therapeutics) at 4.30pm on Direct targeting of NOTCH Transcription Complex by a novel small molecule CB-103 circumvents dose limiting toxicities associated with pan-NOTCH inhibitors.

May 2019

Partnering Meeting Bio€quity Europe

Meet the Cellestia team at the Bio€quity Europe meeting (May 20-21, 2019) in Barcelona.

March 2019

American Association for Cancer Research Meeting

Cellestia selected for an oral presentation on CB-103 by Dr. Raj Lehal, Chief Scientific Officer, at the Preclinical Drug Development session of the American Association for Cancer Research Meeting (Atlanta, March 29–April 3).

February 2019

IND accepted by the FDA

On Feb. 4th, Cellestia received the green light from the FDA for its Investigational New Drug Application (IND). The FDA completed its review, and concluded that Cellestia can proceed with its clinical investigation of CB-103 in tumors driven by an oncogenic NOTCH signaling pathway.

December 2018

Cellestia Biotech AG secures CHF 20 million in Series A funding

Cellestia announced today the close of a CHF 20 million Series A financing round. The financing will accelerate Cellestia’s ongoing clinical program, and advance its innovative R&D pipeline.
To read Cellestia’s press release click here.

September 2018

Cellestia Winner of Venture Leaders China 2018

Cellestia selected as one of the 10 high growth Swiss start-ups composing the new Swiss National Startup Team. The team will fly to China for an exclusive 10-day roadshow for business and investor meetings in September organised by Venture Leaders / swissnex China, including the World Economic Forum Annual Meeting of New Champions in Tianjin

September 2018

Cancer Care 2018

Oral presentation on CB-103 by Dr. Dirk Weber, Chief Medical Officer, at the “Cancer Care 2018 Innovation & Progress in Switzerland” meeting (Bern, September 14).

July 2018

Gordon Research Conference

Oral presentation on CB-103 by Dr. Raj Lehal, Chief Scientific Officer, at the “Notch, Cancer and Therapeutics” session of the Gordon Research Conference on Notch Signaling in Development, Regeneration and Disease (Lewiston, July 22–27).

July 2018

European Congress on Biotechnology

Dr. Raj Lehal, Chief Scientific Officer, has given an oral presentation at the European Congress on Biotechnology (Geneva, July 1–4).